Sygnature Discovery is a leading independent provider of integrated drug discovery and pre-clinical company. Our mission is to accelerate potential new medicines from the lab bench into the clinic to treat patients with a range of debilitating and life-threatening diseases. Founded in 2004, we operate a fully-enabled research-focused organization with all the professional skills and expertise required to take on board the most demanding of drug discovery programs.

Our drug discovery experience encompasses integrated drug discovery programs, fragment-based drug discovery, target validation, hit identification, Hit-to-Lead and Lead Optimisation projects. Core capabilities include medicinal chemistry, in vitro biology/screening, computational chemistry, DMPK, protein crystallography and in vivo PK/PD. Sygnature works flexibly with clients via a variety of risk share deal structures and FTE-based fee-for-service contracts. We have an enviable track record of success for delivering clinical candidates to clients. As of September 2021, we have delivered 17 clinical candidates (Phases I, II and III) to our clients.